- A. Health Biotechnology
- Areas of activity
- Stem cells
- Medical devices
- Drug development
- Cellular Therapy
- Gene Therapy
- Biomaterials and tissue therapy
- Therapeutic areas
- Analgesia & Pain
- Cardiovascular diseases and circulatory system
- Genetic and rare diseases
- Infectious diseases
- Ophtalmology and optometry
- Blood and lymphatic system
- Digestive system and hepatology
- Kidney and genitourinary system
- Central nervous system
- Respiratory and pulmonary system
- B. Agrifood Biotechnology
- Functional Food
Ferrer is a private pharmaceutical group that works for the wellbeing of society through the promotion of health. It has a direct presence in 26 countries and its products are present in more than 90 territories. Ferrer is characterized by the diversification of its business covering drug prescription, vaccines, molecular diagnostics, OTC and food additives. The company maintains a high investment in R&D of new therapies and diagnostics.
Ferrer is currently active in the clinical development of new drugs in spinal cord injury, infectious diseases and sleep disorders. It also develops projects under the "polypill" concept, as the recently launched Trinomia, to facilitate treatment compliance and the rationalization of costs for the health systems.
Ferrer Advanced Biotherapeutics (FAB), the Biotech Research Division of Ferrer Internacional, identifies, promotes and develops therapeutic and diagnostic projects in collaboration with external groups. Projects, based on cutting-edge technology platforms, provide high added value solutions in fields such as CNS, cardiovascular, oncology, dermatology, ophthalmology and gastroenterology.
Epicup, a new cancer of unknown primary diagnostics system based on epigenetic markers, is the first product fully developed by FAB.